Trevi Therapeutics (NASDAQ: TRVI) — Perfil da empresa, notícias e dados financeiros
Trevi Therapeutics develops treatments for chronic cough and pruritus, leveraging neuroscience to improve patient quality of life.
Trevi Therapeutics
Trevi Therapeutics (NASDAQ:TRVI) focuses on developing treatments for serious conditions related to chronic cough and pruritus by leveraging its expertise in neuroscience. The company is pioneering with Haduvio™ (nalbuphine ER), aiming to address the unmet medical needs in these areas. Trevi Therapeutics is committed to improving the quality of life for patients struggling with debilitating symptoms by advancing its robust clinical programs and exploring new therapeutic avenues. Their objective is not just to innovate within the therapeutic landscape but also to ensure these advancements are accessible to those in need, effectively bridging the gap between groundbreaking research and patient care.
Resumo
Operações
Produtos e/ou serviços de Trevi Therapeutics
- Developing Nalbuphine ER to treat pruritus in diseases such as prurigo nodularis and chronic liver diseases.
- Advancing the understanding of chronic cough in idiopathic pulmonary fibrosis through clinical studies.
- Exploring the potential of Nalbuphine ER in treating chronic kidney disease-related pruritus.
- Investigating the application of Nalbuphine ER for chronic pruritus in hemodialysis patients.
- Researching the effectiveness of Nalbuphine ER in managing refractory chronic cough.
- Conducting early-stage research into the use of their proprietary compound for additional indications beyond pruritus.
equipe executiva do Trevi Therapeutics
- Jennifer L. GoodCo-Founder, CEO, President, & Director
- James V. CassellaChief Development Officer
- Farrell SimonChief Commercial Officer
- Thomas R. SciasciaCo-Founder & Chief Scientific Officer
- David C. HastingsChief Financial Officer & Principal Financial Officer
- Christopher GallettaController & Chief Accounting Officer
- Katie McManusCommunications Manager
Principais indicadores financeiros
Resultados divulgados pela Trevi Therapeutics , em USD.
- Cap. de mercado
- 1,9 bi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -0.3
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -49,3 mi | -42,8 mi | |
| 0 | -51,5 mi | -47,9 mi | |
| 0 | -33,9 mi | -29,1 mi | |
| 0 | -29,9 mi | -29,2 mi |